One company that should be on your radar is Quintiles Transnational Holdings Inc. (Q). The stock of this biopharmaceutical service provider has seen its Zacks Rank surge over the past four weeks, moving from Buy territory to its current position as a Strong Buy.
A key reason for this move has been the positive trend in the earnings estimate revisions picture. For Q’s full year estimate, we have seen 12 estimates go higher in the past 30 days, compared to none lower. This trend has helped the consensus estimate to trend higher, going from 2.28 cents a share a month ago to its current level at 2.41 cents.
This positive shift in estimates has made some investors take notice and buy the stock. In fact, Q has seen some pretty solid trading lately, as the company has moved higher by 11.7% in the past month.
If Quintiles Transnational can keep up this great momentum on the earnings estimate front and continue to impress analysts, we could see more gains ahead for this company, suggesting that you might want to put Q on your watch list for the future.
Other top-ranked stocks worth considering in this space include BioTelemetry, Inc. (BEAT), Cancer Genetics, Inc. (CGIX) and Covance Inc. (CVD). While BioTelemetry carries a Zacks Rank #1 (Strong Buy), Cancer Genetics and Covance carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
QUINTILES TRANSNATIONAL HOLDINGS (Q): Free Stock Analysis Report
BIOTELEMETRY INC (BEAT): Free Stock Analysis Report
CANCER GENETICS INC (CGIX): Free Stock Analysis Report
COVANCE INC (CVD): Free Stock Analysis Report
Zacks Investment Research